Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...
Because life expectancy and the prevalence of risk factors such as hypertension, obesity and diabetes are rising globally, heart failure (HF) is growing into a major health problem. Impairment of left ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
Heart failure sounds alarming—and rightfully so. Yet approximately 6.5 million Americans currently live with this condition, many with the specific variant called systolic heart failure, and a ...
Demographic, systemic sclerosis (SSc)-specific, and cardiac factors raised the risk for left ventricular systolic dysfunction (LVSD) in a study of patients with SSc. Researchers used the Johns Hopkins ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results